Navigation Links
MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Date:5/5/2009

Results Showing Burden of RSV Disease Presented at Pediatric Academic Societies' Annual Meeting

BALTIMORE, May 5 /PRNewswire/ -- MedImmune today announced results from a recent study it sponsored, performed by the Kaiser Permanente Division of Research in Oakland, CA, assessing risk factors for respiratory syncytial virus (RSV) infection requiring medical treatment in infants born at 33 weeks gestational age [GA] or later. The analysis suggested that even mild prematurity (e.g., babies born 33-36 weeks GA) is associated with increased risk of medically attended RSV infection, and that this risk is higher among infants exposed to supplemental oxygen or assisted ventilation during the neonatal period. These findings were presented at the 2009 Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, Maryland by Dr. Gabriel J. Escobar.

RSV is a leading cause of viral respiratory infection among preterm infants. Although prematurity is a known risk factor for severe RSV infection, there is little information available on risk factors among moderately (rather than extremely) premature babies.

"The health risks associated with late-preterm birth may be overlooked or misunderstood because these babies often appear as healthy as full-term infants. This study contributes to the growing evidence that, late-preterm infants face greater morbidity and healthcare costs up to at least one year after birth," noted Parthiv Mahadevia, M.D., senior director, health outcomes and pharmacoeconomics, MedImmune. "In particular, babies born between 33 and 36 weeks GA have under-developed respiratory and immune systems, putting them at heightened risk for severe RSV disease. Doctors, parents, and the health care system should be aware of these babies' specialized health needs.

This study sought to quantify the relationships between neonatal characteristics and the occurrence of RSV infection requiring medica
'/>"/>

SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
4. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
5. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
7. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
8. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
9. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
10. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...f.,Nov.25/PRNewswire/--PraxisElectronicMedicalReco...fFamilyPhysicians,(AAFP)FamilyPracticeManagement(F...lquality,healthmaintenance,anddiseasemanagement,al...anked#1amongdoctorsindicatingtheirEMRhadapositivee...nkednumberoneinthecountryinprovidingexcellenttrain...
(Date:11/25/2009)...Nov.25/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasd...ittedtodiscovering,developingandcommercializingnov...ultsforthefiscalyearendedSeptember30,2009.AtSeptem...ivalentsandshortterminvestments. ,, PipelineUp...e2bTrial ,, InlateNovember2009,anindependentD...
(Date:11/25/2009)....,Nov.25/PRNewswire/--TheFDAgrantedtraditionalappr...leosidereversetranscriptaseinhibitor(NNRTI).INTELE...tment-experiencedadultswhoareexperiencingvirologic...ntiretroviral(ARV)agents.Thetraditionalapprovalisb...andDUET-2.INTELENCEiscurrentlymarketedintheU.S.byT...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Rabies 3A How to Protect Yourself and Your Pets 51990 1Rabies 3A How to Protect Yourself and Your Pets 51990 2Sanford Rose Associates Opens Minneapolis Office 13075 1Sanford Rose Associates Opens Minneapolis Office 13075 2Econiche 28TM 29 Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 51988 1Econiche 28TM 29 Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 51988 2Econiche 28TM 29 Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 51988 3Econiche 28TM 29 Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 51988 4Econiche 28TM 29 Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 51988 5Econiche 28TM 29 Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 51988 6
..., Jan. 7 Hyperion,Therapeutics, Inc., a privately...elopment and commercialization of hepatology and g...underserved patient populations with,unmet medical...been elected,to its Board of Directors and will se...cgi-bin/prnh/20070905/AQW076LOGO ), Mr. Ringo bri...
... AtriCure, Inc.,(Nasdaq: ATRC ), a medical device... products, today announced that results reporting ...oducts, which physicians have adopted to,treat atr...s of Thoracic,Surgery by Dr. James H. Wudel, a pro...braska Heart Hospital, Lincoln, Nebraska., Dr. Wu...
Other Medicine Technology:William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman 2Positive Results Published Using AtriCure Minimally Invasive Products 2Positive Results Published Using AtriCure Minimally Invasive Products 3Positive Results Published Using AtriCure Minimally Invasive Products 4
(Date:11/26/2009)... No more letters from the North Pole,...ed text messages from Santa , ...rease operational efficiencies at the North Pole S...ep children all over the globe informed of his Chr...nta’s research department have identified a ...
(Date:11/25/2009)...A,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmostpeo...hiropractorcanalsogivepatientsthehelptheyneed.TMJs...urjaw(mandible)contacts/connectswithyourskull(temp...thTMJdysfunctionarepainwithchewing,clickingorpoppi...ysfunctionincluding:headaches,fatigue,sleepdisturb...
(Date:11/25/2009)...BEACH,Calif.,Nov.25/PRNewswire/--Thanksgivingmeals...sinthegreaterLongBeachareathankstoFaithInAction/Vo...ceatHome(IAH),adivisionofSCANHealthPlan.Formoretha...lunteerstodeliverwarmThanksgivingmealstoseniorsinn...osAngelesandsurroundingcities. ,, "Ourwarmholid...
(Date:11/25/2009)...survivors of testicular cancer who were treated wi...de effects, including neurological side effects an...eated with chemotherapy, according to a new study ...e National Cancer Institute . , Marianne Brydy, ...versity Hospital, in Bergen, Norway, and colleague...
(Date:11/25/2009)...lready used to fight rheumatoid arthritis, could h... , WEDNESDAY, Nov. 25 (HealthDay News) -- A dr...nd rheumatoid arthritis now also shows some promis...diabetes. , The drug, rituximab (Rituxan), help...in, even though the disease had destroyed some of ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
... research that delivers,timely studies with operat...nsulting and early-stage commercialization is now ... research repository managed by research and,consu... links to each of the two new,studies at this addr...
...ges, effort to reduce costs , , ST. LOUIS, Feb. 9...unced today it is in the process of reducing its w... part of an overall cost-cutting program as the co...y suspension of product manufacturing and shipment...
...ith the holiday from fruit and wine to massage can..., Mich., Feb. 9 The sweet delights of Valentine,s...colate, wine and romance can be good for your hear...s, grapes and wine that can lower blood pressure a...
...g Clinicians Exchange (PCE) has formed a partnersh...tion (CDC) to provide immunization continuing educ...ysician assistants (PAs) throughout the United Sta...ut the year as part of the PCE national symposia s...
...ia panel to reveal secrets behind healthy changes ...lling author and RealAge cofounder Michael Roizen,...behavior and patient success when he addresses the...rmed her life, Dr. Roizen will relay insights he,s...
...ire-Asia/ -- Chindex International, Inc.,(Nasdaq: ...of Western healthcare,products and services in the...cial results for the third quarter of fiscal year ...8. Revenue,from the healthcare services division i...
Other Medicine News:Health News:Best Practice Database adds Research Highlighting the Value of Internal Consulting and Early-Stage Commercialization Groups in the Pharmaceutical Industry 2Health News:KV Pharmaceutical Company Reduces Workforce 2Health News:KV Pharmaceutical Company Reduces Workforce 3Health News:KV Pharmaceutical Company Reduces Workforce 4Health News:KV Pharmaceutical Company Reduces Workforce 5Health News:Valentine's Day Indulgences Can Be Heart Healthy 2Health News:Valentine's Day Indulgences Can Be Heart Healthy 3Health News:Practicing Clinicians Exchange Forms Partnership with CDC 2Health News:Oprah Show Expert and RealAge Cofounder Headlines ePharma Talk 2Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 2Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 3Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 4Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 5Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 6Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 7Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 8Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 9Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 10Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 11Health News:Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results 12
BD Visitec Irrigation and Aspiration Cannulas
BD Visiswab Cotton Swab
...ay to eliminate paper ECG systems - without spendi...cally streamlines ECG management in the doctor's o...rtment. You can use ECG manager to quickly sort EC...it patient information, measurements, and analysis...
... Holter Software for Windows is a high-performance...se and maintain as a word processorwith data prese... disclosure, retrospective, prospective superimpos...bines the benefits of prospective and retrospectiv...
Medicine Products: